Atypical Hemolytic Uremic Syndrome Clinical Trial
— STOPECUOfficial title:
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Verified date | December 2019 |
Source | Nantes University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Atypical hemolytic syndrome (aHUS) is a severe renal disease affecting children and adults. It is characterized by the occlusion of intrarenal vessels due to the presence of platelet/fibrin thrombi, and leads to end-stage renal disease in up to 2/3 of patients. The discovery of complement alternative pathway as a major risk factor for aHUS has led to the design of a disease-specific treatment, the anti-C5 monoclonal antibody, eculizumab. Complement inhibition using eculizumab has clearly improved the renal outcome of aHUS patients with a dramatic decrease in the risk of end-stage renal disease. However, the optimal duration of eculizumab therapy is still debated. The present study aims to assess the feasibility and safety of the discontinuation of eculizumab treatment in children and adults with aHUS.
Status | Completed |
Enrollment | 58 |
Est. completion date | December 3, 2019 |
Est. primary completion date | December 3, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years and older |
Eligibility |
Inclusion Criteria: 1. Children and adults under eculizumab treatment for aHUS (initial episode or relapse) defined by at least two of the following: thrombocytopenia (platelet count < 150 G/L), mechanical hemolytical anaemia (Hb < 10 g:dl, LDH > upper limit of normal, undetectable haptoglobin, presence of schizocytes on blood smear), acute kidney injury (serum creatinine and/or proteinuria/creatininuria > upper limit of normal for age or an increase > 15% compared to baseline levels ) 2. Patients not requiring dialysis. 3. Adults: HUS remission and normal or stabilized renal function under eculizumab treatment since at least 6 months (3 months in patients with MCP mutations) 4. Children: age > 3 years at eculizumab withdrawal; HUS remission and normal renal function under eculizumab treatment since at least 3 months in children with isolated MCP mutation, at least 6 months in children with complement mutation other than MCP. Exclusion Criteria: 1. Patients on dialysis. 2. Women treated with eculizumab starting or planning a pregnancy. Pregnancy including the post-partum period is high-risk periods for the occurrence of aHUS. 3. Patients who did not give informed consent. 4. Patients under protection of a judicial authority Patients can be enrolled in the study within ten weeks after Eculizumab stop. |
Country | Name | City | State |
---|---|---|---|
France | CHU Amiens | Amiens | |
France | CHU Bordeaux | Bordeaux | |
France | CHU Caen | Caen | |
France | CH métropole Savoie | Chambéry | |
France | CH Dijon | Dijon | |
France | Ch Le Mans | Le Mans | |
France | CHRU Lille | Lille | |
France | CHU lyon | Lyon | |
France | AP-HM | Marseille | |
France | CH Metz Thionville | Metz | |
France | CHU Montpellier | Montpellier | |
France | CHU Nantes | Nantes | |
France | CHU Nice | NIce | |
France | BICHAT | Paris | |
France | Hôpital Européen Georges Pompidou | Paris | |
France | Hopital Necker | Paris | |
France | Hopital Tenon | Paris | |
France | CHU Rouen | Rouen | |
France | CH Alpes Léman | Sallanches | |
France | CHU Strasbourg | Strasbourg | |
France | Hopital FOCH | Suresnes | |
France | CHU toulouse | Toulouse |
Lead Sponsor | Collaborator |
---|---|
Nantes University Hospital |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The incidence of aHUS relapse during 2 years of follow-up after eculizumab discontinuation | aHUS relapse will be defined by the coexistence of at least two of the following: thrombocytopenia (platelet count < 150 G/L), mechanical hemolytical anaemia (Hb < 10 g/dl, LDH > upper limit of normal, undetectable haptoglobin, presence of schizocytes on blood smear), acute kidney injury (serum creatinine and/or proteinuria/creatininuria > upper limit of normal for age or an increase > 15% compared to baseline levels ), features of thrombotic microangiopathy (glomerular and/or arteriolar thrombi, doubles contours, endothelial cells detachment) in a kidney biopsy, if performed. |
24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
Withdrawn |
NCT03303313 -
A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome
|
Phase 2 | |
Recruiting |
NCT04861259 -
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
|
Phase 3 | |
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Terminated |
NCT02614898 -
Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
|
||
Recruiting |
NCT04958265 -
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
|
Phase 3 | |
Recruiting |
NCT05795140 -
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
|
Phase 3 | |
Completed |
NCT00844844 -
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS
|
Phase 2 | |
Completed |
NCT00844545 -
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS
|
Phase 2 | |
Terminated |
NCT01522170 -
aHUS Observational Long Term Follow-Up
|
N/A | |
Terminated |
NCT02464891 -
Complement Inhibition in aHUS Dialysis Patients
|
Phase 2 | |
Withdrawn |
NCT02626663 -
The Role of Microparticles as a Biomarker
|
||
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Completed |
NCT00838513 -
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
|
Phase 2 | |
Completed |
NCT00844428 -
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS
|
Phase 2 | |
Withdrawn |
NCT03999840 -
Eculizumab to Cemdisiran Switch in aHUS
|
Phase 2 | |
Recruiting |
NCT04889430 -
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
|
Phase 3 | |
Recruiting |
NCT05935215 -
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
|
Phase 3 | |
Recruiting |
NCT03205995 -
Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
|
Phase 3 | |
Recruiting |
NCT05996731 -
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
|
N/A |